

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1600RXA



PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

|      |    |        |   |
|------|----|--------|---|
| NEWS | 1  |        | Web Page for STN Seminar Schedule - N. America  |
| NEWS | 2  | JUN 06 | EPFULL enhanced with 260,000 English abstracts  |
| NEWS | 3  | JUN 06 | KOREAPAT updated with 41,000 documents  |
| NEWS | 4  | JUN 13 | USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications   |
| NEWS | 5  | JUN 19 | CAS REGISTRY includes selected substances from web-based collections  |
| NEWS | 6  | JUN 25 | CA/CAPLUS and USPAT databases updated with IPC reclassification data  |
| NEWS | 7  | JUN 30 | AEROSPACE enhanced with more than 1 million U.S. patent records   |
| NEWS | 8  | JUN 30 | EMBASE, EMBAL, and LEMBASE updated with additional options to display authors and affiliated organizations                      |
| NEWS | 9  | JUN 30 | STN on the Web enhanced with new STN AnaVist Assistant and BLAST plug-in  |
| NEWS | 10 | JUN 30 | STN AnaVist enhanced with database content from EPFULL  |
| NEWS | 11 | JUL 28 | CA/CAPLUS patent coverage enhanced  |
| NEWS | 12 | JUL 28 | EPFULL enhanced with additional legal status information from the EPOline Register  |
| NEWS | 13 | JUL 28 | IFICDB, IFIPAT, and IFIUDB reloaded with enhancements   |
| NEWS | 14 | JUL 28 | STN Viewer performance improved   |
| NEWS | 15 | AUG 01 | INPADOCDB and INPAFAMDB coverage enhanced   |
| NEWS | 16 | AUG 13 | CA/CAPLUS enhanced with printed Chemical Abstracts page images from 1967-1998   |
| NEWS | 17 | AUG 15 | CAOLD to be discontinued on December 31, 2008   |
| NEWS | 18 | AUG 15 | CAPLUS currency for Korean patents enhanced   |
| NEWS | 19 | AUG 27 | CAS definition of basic patents expanded to ensure comprehensive access to substance and sequence information                   |
| NEWS | 20 | SEP 18 | Support for STN Express, Versions 6.01 and earlier, to be discontinued  |
| NEWS | 21 | SEP 25 | CA/CAPLUS current-awareness alert options enhanced to accommodate supplemental CAS indexing of exemplified prophetic substances |
| NEWS | 22 | SEP 26 | WPIDS, WPINDEX, and WPIX coverage of Chinese and Korean patents enhanced  |
| NEWS | 23 | SEP 29 | IFICLS enhanced with new super search field   |
| NEWS | 24 | SEP 29 | EMBASE and EMBAL enhanced with new search and display fields  |
| NEWS | 25 | SEP 30 | CAS patent coverage enhanced to include exemplified prophetic substances identified in new Japanese-language patents            |
| NEWS | 26 | OCT 07 | EPFULL enhanced with full implementation of EPC2000   |
| NEWS | 27 | OCT 07 | Multiple databases enhanced for more flexible patent number searching   |

Uploading C:\Program Files\Stnexp\Queries\QUERIES\10551414.str



chain nodes :  
7 8 9 10 11 12

ring nodes :  
1 2 3 4 5 6

chain bonds :  
4-7 7-8 8-9 9-10 10-11

ring bonds :  
1-6 1-2 2-3 3-4 4-5 5-6

exact/norm bonds :  
4-7 7-8 8-9 9-10 10-11

normalized bonds :  
1-6 1-2 2-3 3-4 4-5 5-6

isolated ring systems :  
containing 1 :

Match level :

1:CLASS 2:CLASS 3:CLASS 4:CLASS 5:CLASS 6:CLASS 7:CLASS 8:CLASS 9:CLASS  
10:CLASS 11:CLASS 12:CLASS 14:CLASS

Generic attributes :

11:

Saturation : Unsaturated  
Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : Exactly 1  
Type of Ring System : Monocyclic

12:

Number of Carbon Atoms : less than 7  
Number of Hetero Atoms : 2 or more  
Type of Ring System : Monocyclic

Element Count :

Node 11: Limited

C,C5

N,N1

Node 12: Limited

C,C3

O,O1

N,N1


S,S0

L1 STRUCTURE UPLOADED

=> d

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 11:15:01 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 29906 TO ITERATE

6.7% PROCESSED 2000 ITERATIONS 0 ANSWERS  
INCOMPLETE SEARCH (SYSTEM LIMIT EXCEEDED)  
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE \*\*COMPLETE\*\*

BATCH \*\*COMPLETE\*\*

PROJECTED ITERATIONS: 587775 TO 608465

PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 full

FULL SEARCH INITIATED 11:15:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 602538 TO ITERATE

100.0% PROCESSED 602538 ITERATIONS 33 ANSWERS  
SEARCH TIME: 00.00.07

L3 33 SEA SSS FUL L1

=> s l3 and caplus/lc

59456180 CAPLUS/LC

L4 32 L3 AND CAPLUS/LC


=> s l3 not l4

L5 1 L3 NOT L4

=> d

L5 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN  
RN 794492-66-3 REGISTRY  
ED Entered STN: 08 Dec 2004  
CN 4-Pyridineacetic acid,  $\alpha$ -[2-[4-(5-oxazolyl)phenyl]hydrazinylidene]-,  
( $\alpha Z$ )- (CA INDEX NAME)  
OTHER CA INDEX NAMES:  
CN 4-Pyridineacetic acid,  $\alpha$ -[[4-(5-oxazolyl)phenyl]hydrazono]-,  
( $\alpha Z$ )- (9CI)  
FS STEREOSEARCH  
MF C16 H12 N4 O3  
CI COM  
SR CA

Double bond geometry as shown.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

```
=> fil caplus
COST IN U.S. DOLLARS          SINCE FILE      TOTAL
                               ENTRY      SESSION
FULL ESTIMATED COST          186.43      188.32
```

FILE 'CAPLUS' ENTERED AT 11:15:31 ON 22 OCT 2008  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 22 Oct 2008 VOL 149 ISS 17  
FILE LAST UPDATED: 21 Oct 2008 (20081021/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the second quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

```
=> d his
```

(FILE 'HOME' ENTERED AT 11:08:36 ON 22 OCT 2008)

FILE 'REGISTRY' ENTERED AT 11:13:42 ON 22 OCT 2008

```
L1          STRUCTURE UPLOADED
L2          0 S L1
L3          33 S L1 FULL
L4          32 S L3 AND CAPLUS/LC
L5          1 S L3 NOT L4
```

FILE 'CAPLUS' ENTERED AT 11:15:31 ON 22 OCT 2008

```
=> s l4
```

```
L6          2 L4
```


```
=> d ibib abs hitstr 1-2
```

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2007:1390731 CAPLUS  
DOCUMENT NUMBER: 148:158944  
TITLE: Orally administered amyloidophilic compounds is effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner  
AUTHOR(S): Kawasaki, Yuri; Kawagoe, Keiichi; Chen, Chun-jen; Teruya, Kenta; Sakasegawa, Yuji; Doh-ura, Katsumi  
CORPORATE SOURCE: Department of Prion Research, Tohoku University Graduate School of Medicine, Sendai, Japan  
SOURCE: Journal of Virology (2007), 81(23), 12889-12898  
CODEN: JOVIAM; ISSN: 0022-538X  
PUBLISHER: American Society for Microbiology  
DOCUMENT TYPE: Journal  
LANGUAGE: English  
AB The establishment of effective therapeutic interventions for prion diseases is necessary. We report on a newly developed amyloidophilic compound that displays therapeutic efficacy when administered orally.  
This compound inhibited abnormal prion protein formation in prion-infected neuroblastoma cells in a prion strain-dependent manner: effectively for RML prion and marginally for 22L prion and Fukuoka-1 prion. When the highest dose (0.24 [wt/wt] in feed) was given orally to cerebrally RML prion-inoculated mice from inoculation until the terminal stage of disease, it extended the incubation periods by 2.3 times compared to the control. The compound exerted therapeutic efficacy in a prion strain-dependent manner such as that observed in the cell culture study:  
most effective for RML prion, less effective for 22L prion or Fukuoka-1 prion, and marginally effective for 263K prion. Its effectiveness depended on  
an earlier start of administration. The glycoform pattern of the abnormal prion protein in the treated mice was modified and showed predominance of the diglycosylated form, which resembled that of 263K prion, suggesting that diglycosylated forms of abnormal prion protein might be least sensitive or resistant to the compound. The mechanism of the prion strain-dependent effectiveness needs to be elucidated and managed. Nevertheless, the identification of an orally available amyloidophilic chemical encourages the pursuit of chemotherapy for prion diseases.  
IT 774236-55-4  
RL: PAC (Pharmacological activity); PKT (Pharmacokinetics); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(orally administered amyloidophilic compds. are effective in prolonging the incubation periods of animals cerebrally infected with prion diseases in a prion strain-dependent manner)  
RN 774236-55-4 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)

L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN  
ACCESSION NUMBER: 2004:857547 CAPLUS  
DOCUMENT NUMBER: 141:350174  
TITLE: Preparation of benzaldehyde or heterocycle carboxaldehyde hydrazone derivatives as inhibitors of agglutination and/or deposition of an amyloid protein or amyloid-like protein  
INVENTOR(S): Kawagoe, Keiichi; Motoki, Kayoko; Odagiri, Takashi; Suzuki, Nobuyuki; Chen, Chun-Jen; Mimura, Tetsuya  
PATENT ASSIGNEE(S): Daiichi Pharmaceutical Co., Ltd., Japan  
SOURCE: PCT Int. Appl., 236 pp.  
CODEN: PIXXD2  
DOCUMENT TYPE: Patent  
LANGUAGE: Japanese  
FAMILY ACC. NUM. COUNT: 1  
PATENT INFORMATION:  


| PATENT NO.  | KIND | DATE     | APPLICATION NO. | DATE       |
|---|------|----------|-----------------|------------|
| WO 2004087641   | A1   | 20041014 | WO 2004-JP4607  | 20040331   |
| W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, GU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW |      |          |                 |            |
| RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG  |      |          |                 |            |
| CA 2521056  | A1   | 20041014 | CA 2004-2521056 | 20040331   |
| EP 1612204  | A1   | 20060104 | EP 2004-724752  | 20040331   |
| R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK   |      |          |                 |            |
| US 20060276433  | A1   | 20061207 | US 2005-551414  | 20050930   |
| PRIORITY APPLN. INFO.:  |      |          | JP 2003-94257   | A 20030331 |
|   |      |          | WO 2004-JP4607  | W 20040331 |

  
OTHER SOURCE(S): MARPAT 141:350174  
GI




AB Comps. represented by the general formula (I), salts thereof, or solvates  
of either (R1, R2 = H, alkyl, alkenyl, alkynyl, aralkyl, NH2, alkylamino, cyano, halo, haloalkyl, haloalkenyl, haloalkynyl, CO2H, alkoxy, carbonyl, CONH2, N-alkylcarbamoyl, N,N-dialkylcarbamoyl, N-hydroxyalkylcarbamoyl, each (un)substituted aryl, (un)saturated 5- to 7-membered heterocyclyl, (un)saturated bi- or tricyclic condensed heterocyclyl, arylalkenyl, (un)saturated heterocyclylalkenyl, or (un)saturated bi- or tricyclic condensed

L6 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)




REFERENCE COUNT: 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE REFORMAT


L6 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN (Continued)  
heterocyclylalkenyl; R3 = H, (un)substituted alkyl, acyl, alkoxy, carbonyl; Ar = a divalent group derived from arom. hydrocarbon, (un)satd. 5- to 7-membered heterocyclic group, or (un)satd. bi- or tricyclic condensed heterocyclic group; X = a single bond, a single bond, each (un)substituted  
linear or branched C1-3 alkylene, C1-3 alkenylene, or C1-3 alkynylene,  
CO; G = halo, haloalkyl, haloalkenyl, haloalkynyl, alkoxy, alkoxy, carbonyl, N-alkylamino, N,N-dialkylamino, each (un)substituted (un)satd. bi- or tricyclic condensed hydrocarbyl, (un)satd. 5- to 7-membered heterocyclyl, or (un)satd. bi- or tricyclic heterocyclyl are prepd. Also disclosed is (1) an agent for inhibiting the agglutination and/or deposition of an amyloid protein or amyloid-like protein or (2) a preventive and/or remedy for conformational diseases or diseases caused by amyloid accumulation, which contains the compd. I, its salt, or solvate thereof. In particular,  
disclosed is a preventive and/or remedy for Alzheimer's disease, Down's syndrome, Creutzfeldt-Jakob disease, type II diabetes, dialysis amyloidosis, AA amyloidosis, Gerstmann-Straussler-Scheinker (GSS) syndrome, Muckle-Wells syndrome, localized atrial amyloidosis, thyroid medullary carcinoma, skin amyloidosis, localized tuberous amyloidosis, AL amyloidosis, AH amyloidosis, familial Mediterranean fever, Parkinson's disease, tauopathy, ALS, or CAG repeat disease. A radiodiagnostic agent contg. radionuclide-labeled, in particular radioactive iodine-labeled compd. I is also disclosed. Thus, 1.0 g 4-(oxazol-5-yl)phenylhydrazine and 0.61 g 4-pyridinecarboxaldehyde were heated in ethanol at reflux overnight to give, after recrystn. from ethanol, 1.03 g 4-pyridinecarboxaldehyde N-[4-(oxazol-5-yl)phenyl]hydrazone (II). II inhibited the formation of amyloid from amyloid  $\beta$  protein with IC50 of 2.94  $\mu$ M vs. 0.87 and 3.23  $\mu$ M for Cogo Red and 2-(1,1-dicyanopropen-2-yl)-6-dimethylaminonaphthalene (DDNP), resp.  
IT 774236-55-4  
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)  
(preparation of benzaldehyde or heterocycle carboxaldehyde hydrazone derivs. as inhibitors of agglutination and/or deposition of amyloid protein or amyloid-like protein)  
RN 774236-55-4 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)




IT 774236-56-5P 774236-57-6P 774236-58-7P  
 774236-59-8P 774236-60-1P 774236-61-2P  
 774236-62-3P 774236-70-3P 774236-71-4P  
 774236-75-8P 774236-80-5P 774236-83-8P  
 774236-91-8P 774236-92-9P 774237-28-4P  
 774237-29-5P 774237-34-2P 774237-35-3P  
 774237-36-4P 774237-37-5P 774237-67-1P  
 774237-68-2P 774237-69-3P 774237-70-6P  
 774237-74-0P 774237-77-3P 774237-78-4P  
 774237-79-5P 774237-80-8P 774237-81-9P  
 774237-86-4P  
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU  
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES  
 (Uses)  
 (preparation of benzaldehyde or heterocycle carboxaldehyde hydrazone  
 derivs.  
 as inhibitors of agglutination and/or deposition of amyloid protein or  
 amyloid-like protein)  
 RN 774236-56-5 CAPLUS  
 CN Hydrazinecarboxylic acid, 1-[4-(5-oxazolyl)phenyl]-2-(4-  
 pyridinylmethylene)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 774236-57-6 CAPLUS  
 CN Acetic acid, 1-[4-(5-oxazolyl)phenyl]-2-(4-pyridinylmethylene)hydrazide  
 (CA INDEX NAME)




RN 774236-58-7 CAPLUS  
 CN 4-Pyridinecarboxaldehyde, 2-methyl-2-[4-(5-oxazolyl)phenyl]hydrazone (CA  
 INDEX NAME)




RN 774236-59-8 CAPLUS  
 CN Hydrazinecarboxylic acid, 1-[4-(4-iodo-5-oxazolyl)phenyl]-2-(4-  
 pyridinylmethylene)-, 1,1-dimethylethyl ester (CA INDEX NAME)




RN 774236-60-1 CAPLUS  
 CN 4-Pyridinecarboxaldehyde, 2-[4-(4-iodo-5-oxazolyl)phenyl]hydrazone (CA  
 INDEX NAME)



RN 774236-61-2 CAPLUS  
 CN 4-Pyridinecarboxaldehyde, 2-[3-(5-oxazolyl)phenyl]hydrazone (CA INDEX  
 NAME)




RN 774236-62-3 CAPLUS  
 CN 4-Pyridinecarboxaldehyde, 2-[2-(5-oxazolyl)phenyl]hydrazone (CA INDEX  
 NAME)




RN 774236-70-3 CAPLUS  
 CN Hydrazinecarboxylic acid,  
 1-[4-[4-(hydroxymethyl)-5-oxazolyl]phenyl]-2-(4-  
 pyridinylmethylene)-, 1,1-dimethylethyl ester (CA INDEX NAME)








RN 774236-71-4 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-[4-(4-(hydroxymethyl)-5-oxazolyl)phenyl]hydrazide (CA INDEX NAME)



RN 774236-75-8 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-[4-(4,5-dihydro-2-oxazolyl)phenyl]hydrazide (CA INDEX NAME)




RN 774236-92-9 CAPLUS  
CN 3-Pyridinecarboxaldehyde, 2-[4-(5-oxazolyl)phenyl]hydrazide (CA INDEX NAME)




RN 774237-28-4 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-[2-iodo-4-(5-oxazolyl)phenyl]hydrazide (CA INDEX NAME)


RN 774236-80-5 CAPLUS  
CN Methanone, phenyl-4-pyridinyl-, 2-[4-(5-oxazolyl)phenyl]hydrazide (CA INDEX NAME)




RN 774236-83-8 CAPLUS  
CN Ethanone, 1-(4-pyridinyl)-, 2-[4-(5-oxazolyl)phenyl]hydrazide (CA INDEX NAME)




RN 774236-91-8 CAPLUS  
CN 2-Pyridinecarboxaldehyde, 2-[4-(5-oxazolyl)phenyl]hydrazide (CA INDEX NAME)




RN 774237-29-5 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-[3-iodo-4-(5-oxazolyl)phenyl]hydrazide (CA INDEX NAME)




RN 774237-34-2 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 3-iodo-, 2-[4-(5-oxazolyl)phenyl]hydrazide (CA INDEX NAME)




RN 774237-35-3 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-iodo-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)




RN 774237-36-4 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-fluoro-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)




RN 774237-37-5 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-(4-methyl-1-piperazinyl)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)



RN 774237-67-1 CAPLUS  
CN 4-Pyridinecarboxaldehyde, 2-(dimethylamino)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)




RN 774237-68-2 CAPLUS  
CN 3-Pyridinecarboxaldehyde, 6-fluoro-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)




RN 774237-69-3 CAPLUS  
CN 3-Pyridinecarboxaldehyde, 6-(4-methyl-1-piperazinyl)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)


PAGE 1-A




PAGE 2-A



RN 774237-70-6 CAPLUS  
CN 3-Pyridinecarboxaldehyde, 6-(dimethylamino)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)




RN 774237-74-0 CAPLUS  
 CN 4-Pyridinecarboxaldehyde, 1,2,3,6-tetrahydro-1-(phenylmethyl)-, 2-[4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)




RN 774237-77-3 CAPLUS  
 CN 4-Pyridineacetic acid,  $\alpha$ -[2-[4-(5-oxazolyl)phenyl]hydrazinylidene]-, ethyl ester, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 774237-80-8 CAPLUS  
 CN 4-Pyridineacetamide, N-(2-hydroxyethyl)- $\alpha$ -[2-[4-(5-oxazolyl)phenyl]hydrazinylidene]-, ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.




RN 774237-81-9 CAPLUS  
 CN 4-Pyridinecarboxaldehyde, 2-[3-fluoro-4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)




RN 774237-78-4 CAPLUS  
 CN 4-Pyridineacetic acid,  $\alpha$ -[2-[4-(5-oxazolyl)phenyl]hydrazinylidene]-, hydrochloride (1:1), ( $\alpha$ Z)- (CA INDEX NAME)

Double bond geometry as shown.




● HCl

RN 774237-79-5 CAPLUS  
 CN 4-Pyridineacetamide,  $\alpha$ -[2-[4-(5-oxazolyl)phenyl]hydrazinylidene]- (CA INDEX NAME)



RN 774237-86-4 CAPLUS  
 CN 4-Pyridinecarboxaldehyde, 2-[3-fluoro-4-(5-oxazolyl)phenyl]hydrazone (CA INDEX NAME)



REFERENCE COUNT: 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE  
 FORMAT

=> log y

COST IN U.S. DOLLARS

SINCE FILE  
ENTRY

TOTAL  
SESSION

FULL ESTIMATED COST

11.38

199.70

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE  
ENTRY

TOTAL  
SESSION

CA SUBSCRIBER PRICE

-1.60

-1.60

STN INTERNATIONAL LOGOFF AT 11:15:43 ON 22 OCT 2008